tiprankstipranks
Trending News
More News >
Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ:TELO
US Market

Telomir Pharmaceuticals, Inc. (TELO) Income Statement

Compare
205 Followers

Telomir Pharmaceuticals, Inc. Income Statement

Last quarter (Q3 2025), Telomir Pharmaceuticals, Inc.'s total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Telomir Pharmaceuticals, Inc.'s net income was $-1.10M. See Telomir Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 12.24M$ 3.94M$ 854.15K$ 138.13K
Depreciation and Amortization
$ 12.24M$ 0.00$ 854.15K$ 138.13K
EBITDA
$ 48.00K$ -11.43M$ 0.00$ 0.00
Operating Income
$ -12.24M$ -3.94M$ -854.15K$ -138.13K
Other Income/Expenses
$ -4.29M$ -9.13M$ 0.00$ 0.00
Pretax Income
$ -16.53M$ -13.07M$ -854.15K$ -138.13K
Net Income
$ -16.53M$ -13.07M$ -854.15K$ -138.13K
Per Share Metrics
Basic EPS
$ -0.56$ -0.44$ -0.03$ 0.00
Diluted EPS
$ -0.56$ -0.44$ -0.03$ 0.00
Weighted Average Shares Outstanding
29.54M 29.61M 29.61M 29.61M
Weighted Average Shares Outstanding (Diluted)
29.54M 29.61M 29.61M 29.61M
Currency in USD

Telomir Pharmaceuticals, Inc. Earnings and Revenue History